Late-Breaking Research: Experimental and Molecular Therapeutics 4

• LB454 · PDF Complete restoration of p53 in p53 mutant cancers through co-delivery of p53 siRNA and mRNA using a targeted LNP platform Heewon Song, Seungwon Lee, Sung Eun Lee, Dongryul Oh, Changhoon Choi, Dae-Hyuk Kweon
• LB455 Preclinical efficacy and biomarker characterization of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent Fritiof Åkerström, Xavier Catena, Marta Santiago, Ana Perego, Ruixian Liu, Arun Sundaramurthy, Lihan Xie, Emilie Renaud, Andreea-Medeea Matei, Xiaoli Huang, Emma Leire, Ozcan Met, Inge-Marie Svane, Shane Olwill, Cristiana Pires, Filipe Pereira, Fabio Rosa
• LB456 · PDF Her2-targeted p53 mRNA-LNP platform: A novel strategy for overcoming radioresistance in p53-deficient ovarian cancer Sung Eun Lee, Arang Son, Yeeun Kim, Ji Won Lee, Heewon Song, Changhoon Choi, Dongryul Oh, Dae-Hyuk Kweon
• LB457 Ribonucleotide reductase inhibition triggers ferroptosis in genetically defined NSCLC Triparna Sen
• LB458 · PDF Restoring a telomere dependent Hayflick limit to treat hematological malignancies Harouna Ousmane Sow, Sabine Mai, Macoura Gadji
• LB459 BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted therapeutics by inhibiting the development of acquired resistance Alastair H. Kyle, Judit P. Banath, Sevin Teymori, Ela Smiljanic-Hurley, Simon Osborne, Jay Paquette, Steve Arns, Claudio Sturino, Joseph Mancini, Andrew I. Minchinton
• LB460 Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models Christine Moomau, Jiaqi Liang, Jian Lin, Xiaozhi Yang, Wenheng Liang, John Campbell, Yipin Lu, David Pirovich, Tao Ji, Lina Gu, Fang Li, Yaoyu Chen, Xiang Zhai
• LB461 In situ measurement of PARP1 activity and trapping at single-strand DNA breaks Franek Sierpowski, Katarzyna Fryt, Jakub Lechowski, Zsombor Prucsi, Agnieszka Waligórska, Magdalena Kordon-Kiszala, Kamil Solarczyk
• LB463 · PDF Exploring the molecular landscape of ovarian cancer through immunohistochemistry multi-marker prevalence screening Eileen Black, Mycah Sewell, Devika Bahal, Jacob Lewis, Salome Tchotorlishvili, Karen Kirchner, Noreen McBrearty
• LB464 PCDC5RP deficiency leads to metabolic abnormalities in pyrimidine-associated pathways, driving genetic instability in cancer cells Hyunjin Shin, Mi-Yeun Kim, Jong-kuk PARK
• LB465 · PDF Establishing quantitative image analysis driven multiplex immunofluorescence panels for retrospective clinical research Salome Tchotorlishvili, Brigham Rhoads, Sarah Gordon, Luke Szyszkiewicz, Jacob Lewis, Karen Kirchner, Noreen McBrearty
• LB466 · PDF Scalable, digitally enabled FISH workflows for high-confidence HER2 and genomic biomarker assessment in precision oncology Julianna Buccafuri, Christine Hale, Jess Dhillon, Richard Siderits, Greg Cesarone
• LB467 Dose optimization and exposure-response (ER) analysis for PF-08634404, an investigational anti-PD-1 and anti-VEGF bispecific antibody Erik Hahn, Alan Liu, Donald Irby, Nathan Braniff, Mary Campbell, Xiasong Zhang, Manisha Lamba, Donghua Yin, Mohamed Elmeliegy, Jennifer Hibma
• LB468 Pharmacokinetics of ALETA-001, a CRUK first-in-human phase I/II trial in patients who have received anti-CD19 CAR T-cell therapy for B-cell malignancies Martin Galler, David Jamieson, Paul Rennert, Jenny Craigen, Gareth Veal
• LB469 Pharmacokinetics of the EP4 antagonist HTL0039732, a CRUK first-in-human phase I trial in patients with advanced solid tumours Dan Astley, Shelby Barnett, Bristi Basu, Debashis Sarker, Natalie Cook, Stefan N. Symeonides, Svatopluk Svetlik, Derrick Spencer-Briggs, Graeme Scarfe, Nigel Swain, Gareth J. Veal
• LB470 · PDF Rational engineering of nanobody pharmacokinetics and linker chemistry to maximize targeted radiotherapy efficacy Yogindra Vedvyas, Nathaniel R. Fredette, Yoo-Shin Kim, Yang Yanping, Benedict Law, Moonsoo Jin
• LB471 · PDF Engineering biologic radiopharmaceuticals with lower unspecific organs uptake Leticia Maria de Souza Cordeiro, Kelley Diaz, Argin Aivazian, Fang Jia, Zheng Liu, Michael P. Wheatcroft, Alessandro Mascioni
• LB472 · PDF Theranostic 89 Zr/ 225 Ac anti-CEACAM5 radioimmunotherapy for metastatic castration-resistant prostate cancer Ambika Parmar, Samuel F. Ruder, Niloufer Salehi, Edward K. Fung, Hong Su, Sandra Huicochea Castellanos, Nai-Kong V. Cheung, David S. Rickman, Scott T. Tagawa, Sarah M. Cheal
• LB473 JNJ-95437446: Discovery and preclinical characterization of an amivantamab-based EGFR/MET-ADC for solid tumor indications Benjamin Henley, Linxiao Chen, Megan Siani, Swetha Rao, Yi Fan, Kristen Wiley, Steve Pomerantz, Shalom Goldberg, Onyi Irrechukwu, Simone Buraschi, Suresh Kumar Swaminathan, Krista Burke, Tammy Bush, Bethany Mattson, Heather Deutsch, Gerald Chu, Jacalyn Clawson, Wan Cheung Cheung, Joshua M. Bauml, Ulrike Philippar, Smruthi Vijayaraghavan
• LB474 · PDF Impact of first-line (1L) amivantamab-lazertinib vs osimertinib on second-line (2L) progression-free survival (PFS) David R. Spigel, Danny Nguyen, Hidetoshi Hayashi, Byoung Chul Cho, Sanjay Popat, James Chih-Hsin Yang, Scott Owen, Antonio Passaro, Clarissa Baldotto, Julian Kam, Seema Sethi, Sujay Shah, Jiarui Zhang, Joshua C. Curtin, Nicolas Girard, William N. William Jr
• LB476 Combined inhibition of transcription initiation and histone deacetylation triggers blood cancer cell death Jennifer Rose Devlin, Shenali Ranasinghe, Ben Martin, Nenad Bartonicek, Kaylene J. Simpson, Ricky W. Johnstone
• LB477 · PDF Neoadjuvant chemotherapy induces clinically distinct spatial remodeling of the tumor microenvironment in PDAC Hyun Jung Kim, Se Hui Jeong, Sujie Lee, Jung Kyoon Choi, In Kyong Shim, Kyung-Gon Kim, Seung Mo Hong, Woohyung Lee, Do-hyun Park, Seung-Jae Myung, Chanho Park, Seo Hye Park, Dongjoo Lee, Song Cheol Kim
• LB478 · PDF Epigenetic inactivation of CTHRC1 promotes immune suppressive microenvironment and cancer metastatic relapse Jae Young So, Tiffany Andohkow, Wooyong Park, Cui Kairong, Qingsong Tang, Gangqing Hu, Alexei Lovanov, Jing Bian, Maggie Cam, Keji Zhao, Li Yang

在完整检索应用中浏览本分会场 →